Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.39 |
| ▸ | BPTF | Q12830 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690913 | 0.91 | HTT (0.48) | GBA1ADORA2AADORA1HTTTSHR | |
| SCHEMBL19691074 | 0.90 | AURKA (0.48) | GBA1HTTSMN1; SMN2ABCG2ALDH1A1 | |
| SCHEMBL19690893 | 0.87 | AURKA (0.47) | GBA1ADORA2AADORA1HTTTSHR | |
| SCHEMBL19691065 | 0.84 | HTT (0.43) | GBA1ADORA2AADORA1HTTSMN1; SMN2 | |
| SCHEMBL19690912 | 0.84 | BPTF (0.43) | GBA1ADORA2AADORA1TSHRNPSR1 | |
| SCHEMBL19690860 | 0.84 | HTT (0.43) | GBA1ADORA2AADORA1HTTTSHR | |
| SCHEMBL19690943 | 0.83 | ADORA2A (0.59) | GBA1ADORA2AADORA1SMN1; SMN2LMNA | |
| SCHEMBL19691024 | 0.82 | BPTF (0.43) | GBA1ADORA2AADORA1TSHRNPSR1 | |
| SCHEMBL19690876 | 0.82 | AURKA (0.48) | GBA1ADORA2AADORA1TSHRNPSR1 | |
| SCHEMBL19690977 | 0.81 | CTSC (0.50) | SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | GBA1 466/4885ADORA2A 1792/4885ADORA1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.